The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC

Phase III COMBI-d Study of Dabrafenib and Trametinib in Patients With Melanoma

Keith T. Flaherty, MD
Published Online: 5:10 PM, Tue June 14, 2016


Keith T. Flaherty, MD, Massachusetts General Hospital Cancer Center and professor of Medicine, Harvard Medical School, provides an overview of the phase III COMBI-d study, which examined the combination of dabrafenib (Tafinlar) and trametinib (Mekinist) as a treatment of patients with BRAF-mutant metastatic melanoma.

Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.